Carlos Escande
YOU?
Author Swipe
View article: eLife Assessment: C-C chemokine receptor 4 deficiency exacerbates early atherosclerosis in mice
eLife Assessment: C-C chemokine receptor 4 deficiency exacerbates early atherosclerosis in mice Open
View article: A nitroalkene derivative of salicylate, SANA, induces creatine-dependent thermogenesis and promotes weight loss
A nitroalkene derivative of salicylate, SANA, induces creatine-dependent thermogenesis and promotes weight loss Open
The emergence of glucagon-like peptide-1 agonists represents a notable advancement in the pharmacological treatment of obesity, yet complementary approaches are essential. Through phenotypic drug discovery, we developed promising nitroalke…
View article: eLife Assessment: C-C chemokine receptor 4 deficiency exacerbates early atherosclerosis in mice
eLife Assessment: C-C chemokine receptor 4 deficiency exacerbates early atherosclerosis in mice Open
View article: Adipocyte-specific deletion of Dbc1 does not recapitulate healthy obesity phenotype but suggests regulation of inflammation signaling
Adipocyte-specific deletion of Dbc1 does not recapitulate healthy obesity phenotype but suggests regulation of inflammation signaling Open
The protein Deleted in Breast Cancer 1 (Dbc1) is an important regulator of various transcription factors and epigenetic modulators, significantly influencing metabolism, obesity, and aging-related processes. Knockout mice lacking Dbc1 exhi…
View article: Abstract 1567 Acetyl-CoA metabolism drives the secretory phenotype in oncogene-induced senescence
Abstract 1567 Acetyl-CoA metabolism drives the secretory phenotype in oncogene-induced senescence Open
View article: Oncogene-induced senescence mitochondrial metabolism and bioenergetics drive the secretory phenotype: further characterization and comparison with other senescence-inducing stimuli
Oncogene-induced senescence mitochondrial metabolism and bioenergetics drive the secretory phenotype: further characterization and comparison with other senescence-inducing stimuli Open
Cellular senescence is characterized by proliferation arrest and a senescence-associated secretory phenotype (SASP), that plays a role in aging and the progression of various age-related diseases. Although various metabolic alterations hav…
View article: eLife Assessment: C-C chemokine receptor 4 deficiency exacerbates early atherosclerosis in mice
eLife Assessment: C-C chemokine receptor 4 deficiency exacerbates early atherosclerosis in mice Open
View article: eLife Assessment: C-C chemokine receptor 4 deficiency exacerbates early atherosclerosis in mice
eLife Assessment: C-C chemokine receptor 4 deficiency exacerbates early atherosclerosis in mice Open
View article: Impact of Bariatric Surgery on metabolic health in a Uruguayan cohort and the emerging predictive role of FSTL1
Impact of Bariatric Surgery on metabolic health in a Uruguayan cohort and the emerging predictive role of FSTL1 Open
Obesity poses significant challenges, necessitating comprehensive strategies for effective intervention. Bariatric Surgery (BS) has emerged as a crucial therapeutic approach, demonstrating success in weight loss and comorbidity improvement…
View article: FSTL1 is an antagonist of ERK1/2 phosphorylation during ciliogenesis and preadipocyte differentiation
FSTL1 is an antagonist of ERK1/2 phosphorylation during ciliogenesis and preadipocyte differentiation Open
FSTL1 is a secreted glycoprotein that is involved in several processes in health and disease, including development, cardiovascular disease, cancer, inflammation, and obesity. The signaling pathways used by FSTL1 to act on target tissues s…
View article: Oncogene-Induced Senescence Mitochondrial Oxidative Metabolism: Further Characterization and Comparison with Hydrogen Peroxide and Doxorubicin Induced Senescence
Oncogene-Induced Senescence Mitochondrial Oxidative Metabolism: Further Characterization and Comparison with Hydrogen Peroxide and Doxorubicin Induced Senescence Open
View article: Oncogene-Induced Senescence Mitochondrial Metabolism and Bioenergetics Drive the Secretory Phenotype: Further Characterization and Comparison with Other Senescence-Inducing Stimuli
Oncogene-Induced Senescence Mitochondrial Metabolism and Bioenergetics Drive the Secretory Phenotype: Further Characterization and Comparison with Other Senescence-Inducing Stimuli Open
View article: CD300f immune receptor contributes to healthy aging by regulating inflammaging, metabolism, and cognitive decline
CD300f immune receptor contributes to healthy aging by regulating inflammaging, metabolism, and cognitive decline Open
View article: A nitroalkene derivative of salicylate alleviates diet-induced obesity by activating creatine metabolism and non-shivering thermogenesis
A nitroalkene derivative of salicylate alleviates diet-induced obesity by activating creatine metabolism and non-shivering thermogenesis Open
View article: Supplementary Figure 4 from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors
Supplementary Figure 4 from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors Open
PDF file - 60K, Effect of another CD38 siRNA on cell viability.
View article: Supplementary Figure 6 from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors
Supplementary Figure 6 from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors Open
PDF file - 141K, mRNA expression in tumor tissues and pancreatic cell lines.
View article: Supplementary Figure Legend from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors
Supplementary Figure Legend from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors Open
PDF file - 44K
View article: Supplementary Figure 6 from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors
Supplementary Figure 6 from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors Open
PDF file - 141K, mRNA expression in tumor tissues and pancreatic cell lines.
View article: supplementary figure legends from SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway
supplementary figure legends from SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway Open
supplementary figure legends S1-S15
View article: Data from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors
Data from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors Open
Purpose: Here, we describe a novel interplay between NAD synthesis and degradation involved in pancreatic tumor growth.Experimental Design: We used human pancreatic cancer cells, both in vitro (cell culture experiments…
View article: CCR Translation for This Article from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors
CCR Translation for This Article from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors Open
CCR Translation for This Article from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors
View article: Supplementary Figure 4 from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors
Supplementary Figure 4 from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors Open
PDF file - 60K, Effect of another CD38 siRNA on cell viability.
View article: Supplementary Figure 1 from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors
Supplementary Figure 1 from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors Open
PDF file - 69K, Effect of FK866 treatment on respiratory parameters of intact pancreatic cancer cells.
View article: Data from SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway
Data from SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway Open
Purpose: Recent studies suggest that SIRT1-activating compounds (STAC) are a promising class of anticancer drugs, although their mechanism of action remains elusive. The main goal of this study is to determine the role of STACs as a…
View article: CCR Translation for This Article from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors
CCR Translation for This Article from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors Open
CCR Translation for This Article from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors
View article: Data from SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway
Data from SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway Open
Purpose: Recent studies suggest that SIRT1-activating compounds (STAC) are a promising class of anticancer drugs, although their mechanism of action remains elusive. The main goal of this study is to determine the role of STACs as a…
View article: Supplementary Figure Legend from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors
Supplementary Figure Legend from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors Open
PDF file - 44K
View article: Supplementary Figure 3 from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors
Supplementary Figure 3 from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors Open
PDF file - 51K, Effect of another NAMPT siRNA on cell growth. PaTu8988t cells were transfected with Nampt siRNA and a non-target siRNA (Control).
View article: supplementary figures from SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway
supplementary figures from SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway Open
supplementary figures S1-15. S1- STAC's inhibition of pancreatic cell viability is greater in low serum conditions. S2-SRT1460 inhibits growth and colony formation of Patu8988t cells. S3-STACs sensitize pancreatic cancer cells to Paclitaxe…
View article: Supplementary Figure 5 from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors
Supplementary Figure 5 from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors Open
PDF file - 66K, CD38 overexpression increases sensitivity to FK866.